Why IMU is a multi multi bagger, page-24154

Finally the Valueadd I once knew, seeing the funny side despite all seriousness.

But you have to agree, something needs to change. And that's what most here want, a change. If Hopper can prove he got his MOJO back then he can stay on, but more transparency regarding PD1-Vaxx and HER-Vaxx is needed.

LC said once that the HER2 market is overcrowded. That sounds like a terrible place to sell anything HER related but if IMU can position itself apart form all the competition and stand out - and the B-cell platform and its data are that different and outstanding - then selling this gem is not a problem. Or we get a nice surprise from the Uni Vienna - Pfizer mRNA cooperation ( researching whether there are any benefits / ways of combining B-cell tech and mRNA ) and Pfizer is offering something. That remote chance could explain why HER-Vaxx has been put on hold. Again, some info from IMU could help to clarify but no comments from neither Joshua Tobias in Vienna nor IMU when I emailed them.

GLTA